ストックスクリーナーアプリを入手
2.92
1.02%
-0.03
前日終値:
$2.95
開ける：
$2.95
24時間の取引高:
347.44K
Relative Volume:
1.51
時価総額：
$81.40M
収益：
-
当期純損益:
$-14.14M
株価収益率:
-3.1739
EPS:
-0.92
ネットキャッシュフロー:
$-12.64M
1週間 パフォーマンス:
+7.75%
1か月 パフォーマンス:
+28.07%
6か月 パフォーマンス:
+43.14%
1年 パフォーマンス:
+33.94%
1日の値動き範囲:
$2.91
$3.12
1週間の範囲:
$2.61
$3.12
52週間の値動き範囲:
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
名前
Immix Biopharma Inc
セクター
電話
(888) 958-1084
住所
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.92 | 75.55M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc (IMMX) 最新ニュース
What makes Immix Biopharma Inc. stock price move sharplyFast Growing Stocks - Newser
How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser
Why Immix Biopharma Inc. stock attracts strong analyst attentionDouble Your Capital Alerts - Newser
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria
Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq
Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire
Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World
Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks
Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewswire
ImmixBio Joins Elite Pharma Leaders at FDA Commissioner's Strategic Forum on Drug Development - Stock Titan
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential - Smartkarma
HC Wainwright Comments on Immix Biopharma Q1 Earnings - Defense World
Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright - Defense World
Immix Biopharma (IMMX) Achieves Significant Clinical Milestone w - GuruFocus
immix biopharma enters at-the-market offering agreement - Investing.com Australia
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial - Investing.com
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC - GuruFocus
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | IMMX Stock News - GuruFocus
Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire
Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com South Africa
Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com South Africa
immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - MarketScreener
Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia
Immix Biopharma Enters At The Market Offering Agreement - TipRanks
Immix Biopharma reports high response rate in AL Amyloidosis trial - Investing.com
Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq
Immix Biopharma Inc (IMMX) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):